Lannett: Pricing Pressure ‘Intensified Beyond Historical Norms’
OTC, Rx Generics Firm ‘Not Sitting Back’ To Address Challenges
Not many firms report a negative EBITDA when adjusted for costs, but this Lannett's fate during its FY2022 Q2. Management addressed challenges for Lannett’s base business and the ways in which it intends to turn the tide in the coming years.
